- 专利标题： Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
-
申请号： US12706819申请日： 2010-02-17
-
公开(公告)号： US08431585B2公开(公告)日： 2013-04-30
- 发明人: Thomas Singer , Stefan Platz , Florian Colbatzky
- 申请人： Thomas Singer , Stefan Platz , Florian Colbatzky
- 申请人地址： DE Ingelheim am Rhein
- 专利权人： Boehringer Ingelheim Pharma GmbH & Co. KG
- 当前专利权人： Boehringer Ingelheim Pharma GmbH & Co. KG
- 当前专利权人地址： DE Ingelheim am Rhein
- 代理商 Michael P. Morris; Anthony P. Bottino
- 优先权： DE10221018 20020511
- 主分类号： A61K31/517
- IPC分类号： A61K31/517
摘要：
The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.
公开/授权文献
信息查询
IPC分类:
